<DOC>
	<DOCNO>NCT01091792</DOCNO>
	<brief_summary>Blood sample obtain newly diagnose GBM patient treat combined radiotherapy ( RT ) , temozolomide ( TMZ ) bevacizumab ( BEV ) specific time point . The primary outcome shift T reg cell fraction define determine proportion CD4 cell CD4+ CD25 .</brief_summary>
	<brief_title>Exploratory Study Modulation Immune System VEGF Blockade Patients With Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>Glioblastoma multiforme ( GBM ) frequent malignant brain tumor remain lethal disease . Approximately 4 week post surgery tumor resection , patient proceed standard care treatment currently consist temozolomide ( TMZ ) concurrent radiation therapy ( RT ) 6 week . This study add bevacizumab ( BEV ) standard care regimen newly diagnose patient . The Bevacizumab add 2 week post start RT/TMZ . Administration bevacizumab continue concurrently TMZ every 2 week 12 month . Blood sample obtain patient 3 different time point study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Histologically proven GBM Karnofsky status equal great 60 % Inadequately control hypertension Prior history hypertension crisis hypertensive encephalopathy History stroke transient ischemic attach within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>GBM</keyword>
	<keyword>Grade IV</keyword>
	<keyword>glioma</keyword>
</DOC>